SOURCE: Corcept Therapeutics

Corcept Therapeutics

January 22, 2015 16:05 ET

Corcept Therapeutics to Announce Fourth Quarter and Full Year 2014 Revenue and Corporate Update and Host Conference Call

MENLO PARK, CA--(Marketwired - Jan 22, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full year 2014 revenue on January 29, 2015. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Conference Call Information

To participate, dial 1-888-771-4371 from the United States or 1-847-585-4405 internationally approximately 10 minutes before the start of the call. The passcode is 38869004.

A replay will be available through February 12, 2015 at 1-888-843-7419 from the United States and +1-630-652-3042 internationally. The passcode is 3886 9004.

About Corcept Therapeutics Incorporated

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders. Korlym, a first generation competitive GR antagonist, is the company's first FDA-approved medication. The company has a Phase 1 trial of mifepristone for the treatment of triple-negative breast cancer, a Phase 1 trial of CORT 125134, one of its proprietary, selective GR-II antagonists, and a portfolio of other selective GR antagonists that competitively block the effects of cortisol but not progesterone. It owns extensive intellectual property covering the use of GR antagonists, including mifepristone, in the treatment of a wide variety of metabolic, oncologic and psychiatric disorders. It also holds composition of matter patents for its selective GR antagonists.

Contact Information